HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pierre-Antoine Bonnet Selected Research

EAPB0503

3/2022EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
11/2018Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells.
11/2018EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica.
1/2018Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice.
1/2016New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure-activity relationships.
7/2014EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells.
1/2014Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry.
10/2010Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
5/2009Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pierre-Antoine Bonnet Research Topics

Disease

10Melanoma (Melanoma, Malignant)
02/2021 - 04/2008
7Neoplasms (Cancer)
12/2020 - 04/2008
3T-Cell Lymphoma (Lymphoma, T Cell)
01/2018 - 04/2008
2Lymphoma (Lymphomas)
10/2010 - 05/2009
1Leukemia
03/2022
1Cutaneous Leishmaniasis
11/2018
1Myeloid Leukemia (Leukemia, Myelocytic)
07/2014
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
07/2014
1Basal Cell Carcinoma (Rodent Ulcer)
04/2008
1Condylomata Acuminata (Genital Wart)
04/2008
1Neoplasm Metastasis (Metastasis)
04/2008
1Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
04/2008
1HIV Infections (HIV Infection)
05/2007

Drug/Important Bio-Agent (IBA)

9EAPB0503IBA
03/2022 - 05/2009
7EAPB0203IBA
11/2018 - 04/2008
6QuinoxalinesIBA
02/2021 - 05/2009
4Imiquimod (Aldara)FDA LinkGeneric
11/2018 - 04/2008
2Biological ProductsIBA
12/2020 - 01/2016
2fotemustine (Muphoran)IBA
01/2010 - 07/2008
1VemurafenibIBA
02/2021
1Amino AcidsFDA Link
11/2018
1TubulinIBA
01/2016
1Imatinib Mesylate (Gleevec)FDA Link
07/2014
1Tyrosine Kinase InhibitorsIBA
07/2014
1Pharmaceutical PreparationsIBA
01/2014
1Protease Inhibitors (Protease Inhibitor)IBA
05/2007
1Anti-Retroviral Agents (Antiretroviral Agents)IBA
05/2007
1NucleosidesIBA
05/2007
1Reverse Transcriptase InhibitorsIBA
05/2007

Therapy/Procedure

2Therapeutics
02/2021 - 04/2008